Expert opinion on the management of renal manifestations of chronic HCV infection

Fabrizio Fabrizi, Francesco Negro, Mark Bondin, Patrice Cacoub

Research output: Contribution to journalArticlepeer-review


Chronic HCV infection is a non-traditional (but modifiable) risk factor for chronic kidney disease and has been implicated in glomerular injury and nephrosclerotic disease. Three HCV direct-acting antiviral regimens are available for patients with severe kidney impairment: ombitasvir, paritaprevir with the pharmacokinetic enhancer ritonavir, and dasabuvir; glecaprevir plus pibrentasvir; and elbasvir plus grazoprevir. In patients with severe kidney impairment, sofosbuvir-free regimens are preferred because sofosbuvir accumulation has been associated with a progressive worsening of renal function. In this Review, we provide our expert opinion on the current HCV treatment paradigm and highlight the remaining issues that need to be overcome to improve the treatment of HCV in this population.

Original languageEnglish
Pages (from-to)57-67
Number of pages11
JournalAntiviral Therapy
Publication statusPublished - Jan 1 2018

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Expert opinion on the management of renal manifestations of chronic HCV infection'. Together they form a unique fingerprint.

Cite this